NY-MEDIAOCEAN
6.3.2024 10:01:33 CET | Business Wire | Press release
Mediaocean, the mission-critical platform for omnichannel advertising, today announced six new partnerships for its Creative Ad Tech platform, Flashtalking, bringing its market leading solutions to more customers in a range of key markets around the world. The agreements provision for primary ad serving, creative personalization, cross-channel measurement and verification across open web display, mobile, audio, video, digital out-of-home, and connected TV.
Collectively, the new activation partners support advertisers in 89 different countries, significantly expanding Flashtalking’s footprint following a surge in adoption after the announcement that Amazon was deprecating its Sizmek ad server. Each of these companies brings deep experience in the ad serving market, having previously supported brands and agencies using Amazon/Sizmek.
Founded in 2001 and acquired by Mediaocean in 2021, Flashtalking is the leading independent ad tech platform, bridging creative and media teams with intelligent, audience-aware insights and workflows at scale and across channels. The Flashtalking platform provides AI and automation to connect the silos between teams for more efficient production, versioning, and distribution of creative.
The new partners include Tailwind, which operates in 36 markets across Central and South Eastern Europe, the Nordics and Middle East North Africa (MENA), empowering businesses to fast track their marketing with technology integrations, strategic consultation, and professional services, as well as Box Digital, a South Africa-based digital advertising services business with customers spanning 8 sub-Saharan African countries.
A partnership with Adsmovil will bolster Flashtalking’s operations within 33 markets across Latin America (LATAM), through a business uniquely focused on Hispanic and Brazilian audiences which currently serves over 4 billion impressions per month. Meanwhile, a new relationship with Adsonice, will grow Flashtalking’s presence across Europe.
Additionally, an agreement with Escape Velocity, a digital media technology services company that supports agencies and advertisers, will scale Flashtalking in India, Korea, Bangladesh, and Sri Lanka while eTechSol will help serve customers in Pakistan.
Simon Thorne, MD EMEA for Flashtalking, commented: “We’ve seen huge appetite for a truly intelligent, dynamic approach to managing and activating creative campaigns. Advertisers need to enable deep personalization, ensuring the most relevant and impactful brand messages reach the right consumers at the right moment, and they want to do it via a single integrated platform. Today’s announcement really cements our position as being the best solution to deliver that on a global level.”
Coming in the wake of Amazon’s announcement that it will be shuttering its ad serving service, these new partnerships represented a unique opportunity to combine Flashtalking’s best-in-class advertising technology with in-market experts who can offer deep local insights and a highly mature ad serving knowledge base.
Flashtalking was recently named a winner of G2 2024 Best Software Awards for Marketing & Digital Advertising Products based on 300+ authenticated customer reviews. The platform was ranked a leader in Enterprise Creative Management Platforms, Cross-Channel, Video, Mobile, Display, and Social Media Advertising.
Georgia Brammer, MD JAPAC for Flashtalking, added, “We’re thrilled to be able to build these new relationships in so many important markets. We’ve been impressed by the drive and knowledge represented by the teams at all of these businesses. This is, on multiple fronts, a time of change in the global advertising sector and, from conversations with major advertisers, the growth potential we’re seeing in further developing this global network is already proving to be really powerful.”
Odysseas Ntotsikas, Managing Partner of Tailwind, stated, “True to Tailwind’s mission to ‘Drive business fast forward’ the power of creative has proved to be the variable with the biggest impact in an omnichannel marketer’s stack. Through this strategic partnership with global leader Flashtalking, we fortify over a decade of operational excellence in empowering hundreds of regional marketers with creative personalization and digital advertising intelligence to win the only war that matters today, the war for attention.”
Alberto Pardo, Founder & CEO of Adsmovil, said, “We, at Adsmovil, have been committed to driving relevance and value to our clients since our inception. Flashtalking furthers our mission and expands the opportunity to better serve clients with personalization based on real-time variables, driving greater congruence and resonance, and a higher advertiser ROI. We are very excited about our partnership.”
Raghu Seelamsetty, MD of Escape Velocity, added, “Escape is delighted to be partnering with Flashtalking. The partnership is well poised to take advantage of the growth of CTV and social media in these fast growing markets. Flashtalking’s market leading technology combined with Escape’s market reach and service capabilities will enable us to deliver world class solutions to our clients.”
About Flashtalking by Mediaocean
Flashtalking unleashes the power of creative to make media work better. As the leading independent platform for personalization and intelligence across all marketing channels, our Creative Ad Tech bridges the gap between creative and media. We provide AI and automation to connect the silos between teams and deliver more efficient production, versioning, and distribution of creative. Our solutions operate at scale across CTV, Video, Display, Social, Native, Audio, DOOH, and Retail Media channels. As part of Mediaocean, Flashtalking is tied into the industry’s core ad infrastructure for omnichannel planning, buying, and billing. Visit flashtalking.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305248528/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
